Psoriasis as initiator or amplifier of the systemic inflammatory march: Impact on development of severe vascular events and implications for treatment strategy

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 7, 2013, Pages 876-883

  Su, Y S ^a,b   Yu, H S ^a   Li, W C ^a   Ko, Y C ^c   Chen, G S ^a   Wu, C S ^b   Lu, Y W ^a   Yang, Y H ^b   Lan, C C E ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; RETINOID;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GENDER; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; PRIORITY JOURNAL; PSORIASIS; RISK FACTOR; SEX DIFFERENCE; SYSTEMIC INFLAMMATION; SYSTEMIC THERAPY; TAIWAN; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; METABOLIC DISEASES; METHOTREXATE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84879117895     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04599.x     Document Type: Article

References (24)

1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. 2): ii14-ii17.
2. Costello PJ, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001; 166: 2878-2886.
3. Curran SA, FitzGerald OM, Costello PJ, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004; 172: 1935-1944.
4. Lan CC, Tsai WC, Wu CS, et al. Psoriatic patients with arthropathy show significant expression of free HLA class I heavy chains on circulating monocytes: a potential role in the pathogenesis of psoriatic arthropathy. Br J Dermatol 2004; 151: 24-31.
5. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123-127.
6. Hayes J, Koo J,. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010; 23: 174-180.
7. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
8. Mease PJ, Menter MA,. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54: 685-704.
9. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
10. Wang WS, Wahlqvist ML, Hsu CC, et al. Age- and gender-specific population attributable risks of metabolic disorders on all-cause and cardiovascular mortality in Taiwan. BMC Public Health 2012; 12: 111.
11. Libby P,. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-358.
12. Boehncke WH, Boehncke S, Schon MP,. Managing comorbid disease in patients with psoriasis. Br Med J 2010; 340: b5666.
13. Boehncke WH, Boehncke S, Tobin AM, et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-307.
14. Hotamisligil GS,. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
15. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
16. Lan CC, Ko YC, Yu HS, et al. Methotrexate reduces the occurrences of cerebrovascular events among taiwanese psoriatic patients: a nationwide population-based study. Acta Derm Venereol 2012; doi:10.2340/00015555-1283. [Epub ahead of print]
17. Tseng CH,. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011; 54: 2009-2015.
18. Chen PC, Muo CH, Lee YT, et al. Lung cancer and incidence of stroke: a population-based cohort study. Stroke 2011; 42: 3034-3039.
19. Davidovici BB, Sattar N, Jorg PC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-1796.
20. Nestle FO, Kaplan DH, Barker J,. Psoriasis. J Invest Dermatol 2009; 361: 496-509.
21. Schmitt J, Ford DE,. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010; 24: 885-892.
22. Knopp RH,. Risk factors for coronary artery disease in women. Am J Cardiol 2002; 89: 28E-34E; discussion 34E-35E.
23. Boehncke S, Fichtlscherer S, Salgo R, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 2011; 303: 381-388.
24. Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011; 25: 1187-1193.